News: Pig hearts have been transplanted into humans for the first time. David Bennett Sr., a man with terminal heart disease, underwent a genetically modified pig heart transplant during an eight-hour operation at the University of Maryland Medical Center on Friday, January 7, according to a statement issued last night. The operation was a last-ditch effort to restore Bennett, 57, who was deemed unfit for a conventional heart transplant. He was hospitalized for more than six weeks before being treated for a life-threatening arrhythmia. “Either die or be replaced,” he said in a press statement. “I want to live. I know it’s a shot in the dark, but it’s my last choice.”
Strategy: Ten genes of donor pigs were mutated before transplantation. Three of these genes are responsible for human organ rejection, so they were discarded. Six genes were inserted to help control the pig’s immune system and an additional gene was injected to stop the pig’s heart tissue from overgrowth.
The Maryland team has used a new experimental drug and a new machine to suppress the immune system and prevent rejection, which is effective up to the pig heart process to ensure that fluid is pushed through the tissue. The FDA allowed the process to proceed urgently on New Year’s Eve Near the New York Times.
What next: Demand for this specialty has grown significantly as a result of recent corporate scandals in the United States, according to the Federal Reserve Health Resources and Services Administration.
Preliminary results look promising for Bennett, who is expected to emerge from the heart-long bypass machine in the hope that he will be closely monitored today (January 11) for any symptoms in the coming days and weeks of rejection or infection.
New border: Although genotransplantation has a long and often failed history of organ or tissue transplantation in humans, new gene-editing technologies are making it more effective. In last week’s operation, the genetically modified pig was supplied by Revivicor, one of several biotech companies working to develop pig organs for transplantation into humans.
Revivikar was also involved in the successful transplantation of a pig’s kidney into a human patient in the end. October, Which was a major milestone in proving the effectiveness of its strategies. As well as Revivicor, Harvard scientist George Church Co-founded a company called eGensisis, Which is working to make animal organs effective for human transplantation using CRISPR gene-editing, although its ambitious proposed timescale has fallen by the wayside.